Children's Oncology Group for standard-risk acute lymphoblastic leukemia, reported by the methotrexate: results of the Children's Cancer Group (CCG) 1952 study fails to improve event-free survival when compared with intrathecal Intrathecal triple therapy decreases central nervous system relapse but

[1]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[2]  N. Heerema,et al.  Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2003, Blood.

[3]  N. Heerema,et al.  Intensification of therapy for children with lower-risk acute lymphoblastic leukemia: long-term follow-up of patients treated on Children's Cancer Group Trial 1881. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  B. Bostrom,et al.  Systemic Methotrexate Exposure Is Greater After Intrathecal Than After Oral Administration , 2003, Journal of pediatric hematology/oncology.

[5]  M. Schrappe,et al.  Diagnostic cerebrospinal fluid examination in children with acute lymphoblastic leukemia: significance of low leukocyte counts with blasts or traumatic lumbar puncture. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Y. Furukawa,et al.  Schedule-dependent synergism and antagonism between methotrexate and cytarabine against human leukemia cell lines in vitro , 2002, Leukemia.

[7]  N. Heerema,et al.  Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 2002, Blood.

[8]  J. Shuster,et al.  Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986–1994 , 2000, Leukemia.

[9]  F. Behm,et al.  Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital , 2000, Leukemia.

[10]  C. Pui,et al.  Long-term results of large prospective trials in childhood acute lymphoblastic leukemia , 2000, Leukemia.

[11]  M. Relling,et al.  Traumatic lumbar puncture at diagnosis adversely affects outcome in childhood acute lymphoblastic leukemia. , 2000, Blood.

[12]  W. Hiddemann,et al.  Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.

[13]  B. Pollock,et al.  Improved survival of children with isolated CNS relapse of acute lymphoblastic leukemia: a pediatric oncology group study . , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Amylon,et al.  Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study , 1999, Leukemia.

[15]  F. Behm,et al.  Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. , 1998, Blood.

[16]  N. Winick,et al.  Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  H. Sather,et al.  Early response to therapy and outcome in childhood acute lymphoblastic leukemia , 1997, Cancer.

[18]  J. Shuster,et al.  Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  S. Shurtleff,et al.  TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. , 1995, Leukemia.

[20]  R. Herrmann,et al.  Correlation of bone marrow minimal residual disease and apparent isolated extramedullary relapse in childhood acute lymphoblastic leukaemia. , 1995, Leukemia.

[21]  S. Azen,et al.  Power considerations for testing an interaction in a 2 x k factorial design with a failure time outcome. , 1994, Controlled clinical trials.

[22]  R Simon,et al.  Some practical aspects of the interim monitoring of clinical trials. , 1994, Statistics in medicine.

[23]  D L DeMets,et al.  Interim analysis: the alpha spending function approach. , 1994, Statistics in medicine.

[24]  S. Woo,et al.  Prevention and treatment of meningeal leukemia in children. , 1994, Blood.

[25]  N. Goulden,et al.  PCR assessment of bone marrow status in ‘isolated’extramedullary relapse of childhood B‐precursor acute lymphoblastic leukaemia , 1994, British journal of haematology.

[26]  R. Mulhern,et al.  9 Long-term sequelae of therapy for childhood acute lymphoblastic leukaemia , 1994 .

[27]  C. Pui,et al.  Molecular evidence for minimal residual bone marrow disease in children with 'isolated' extra-medullary relapse of T-cell acute lymphoblastic leukemia. , 1994, Leukemia.

[28]  F. Behm,et al.  Low leukocyte counts with blast cells in cerebrospinal fluid of children with newly diagnosed acute lymphoblastic leukemia. , 1993, The New England journal of medicine.

[29]  F. Behm,et al.  Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. , 1993, Blood.

[30]  L. Frankel,et al.  Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  H. Sather,et al.  Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Childrens Cancer Group report. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Robison,et al.  Second neoplasms after acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[33]  J. Peto,et al.  Results of Medical Research Council Childhood Leukaemia Trial UKALL VIII (Report to the Medical Research Council on behalf of the Working Party on Leukaemia in Childhood) , 1991, British journal of haematology.

[34]  C. Pochedly.  Prevention of meningeal leukemia. Review of 20 years of research and current recommendations. , 1990, Hematology/oncology clinics of North America.

[35]  H. Sather,et al.  Early response to induction therapy as a predictor of disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: a report from the Childrens Cancer Study Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  J. Shuster,et al.  Treatment intensity and outcome for children with acute lymphocytic leukemia of standard risk. A pediatric oncology group study , 1989, Cancer.

[37]  B. Koller,et al.  Biphenotypic leukemic lymphocyte precursors in CD2+CD19+ acute lymphoblastic leukemia and their putative normal counterparts in human fetal hematopoietic tissues. , 1989, Blood.

[38]  L. Robison,et al.  Long-term evaluation of a CNS prophylaxis trial--treatment comparisons and outcome after CNS relapse in childhood ALL: a report from the Childrens Cancer Study Group. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  S. Sallan,et al.  Brain tumors after cranial irradiation for childhood acute lymphoblastic leukemia. A 13‐year experience from the Dana‐Farber cancer institute and the children's hospital , 1987, Cancer.

[40]  G. Chrousos,et al.  Differences in cerebrospinal fluid penetration of corticosteroids: possible relationship to the prevention of meningeal leukemia. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  S. George,et al.  The importance of an isolated central nervous system relapse in children with acute lymphoblastic leukemia. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Poplack,et al.  Cytosine arabinoside cerebrospinal fluid kinetics , 1984, Clinical pharmacology and therapeutics.

[43]  H. Sather,et al.  Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  J. Belli,et al.  Efficacy and morbidity of central nervous system prophylaxis in childhood acute lymphoblastic leukemia: eight years' experience with cranial irradiation and intrathecal methotrexate , 1983 .

[45]  P. Dyment,et al.  Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a pediatric oncology group study , 1982 .

[46]  R. Simon,et al.  Patient subsets and variation in therapeutic efficacy. , 1982, British journal of clinical pharmacology.

[47]  J. Pullen,et al.  CNS prophylaxis in acute lymphoblastic leukemia. Comparison of two methods a southwest oncology group study , 1982, Cancer.

[48]  R. Spector.  Pharmacokinetics and metabolism of cytosine arabinoside in the central nervous system. , 1982, The Journal of pharmacology and experimental therapeutics.

[49]  H. Sather,et al.  CENTRAL NERVOUS SYSTEM PROPHYLAXIS IN LEUKAEMIA , 1981, The Lancet.

[50]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[51]  Bleyer Aw.  Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. , 1977 .

[52]  G. Humphrey,et al.  Combination intrathecal therapy for meningeal leukemia: two versus three drugs , 1977 .

[53]  F. Valeriote,et al.  The enhanced cytotoxicity of combinations of 1-beta-D-arabinofuranosylcytosine and methotrexate. , 1975, Cancer research.

[54]  M. Tattersall,et al.  Combination chemotherapy: the antagonism of methotrexate and cytosine arabinoside. , 1973, European journal of cancer.

[55]  G. Grindey,et al.  Interaction of drugs inhibiting different steps in the synthesis of DNA. , 1972, Cancer research.

[56]  G. Grindey,et al.  Evaluation of combination chemotherapy in vivo and in culture with l- -D-arabinofuranosylcytosine and 1-formylisoquinoline thiosemicarbazone. , 1972, Cancer research.

[57]  R. Aur,et al.  Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia. , 1971, Blood.

[58]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[59]  R. Gelber,et al.  Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  R. Riccardi,et al.  Intrathecal Chemotherapy With Antineoplastic Agents in Children , 2001, Paediatric drugs.

[61]  G. Leverger,et al.  The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. , 2001, Blood.

[62]  A. Moghrabi,et al.  Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981–1995) , 2000, Leukemia.

[63]  N. Winick,et al.  Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  C. Pui,et al.  Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  W. Kamps,et al.  Dutch Childhood Leukemia Study Group: early results of study ALL VI (1984-1988). , 1990, Haematology and blood transfusion.

[66]  W. Bleyer,et al.  Biology and pathogenesis of CNS leukemia. , 1989, The American journal of pediatric hematology/oncology.

[67]  J. Ochs,et al.  Neurotoxicity due to central nervous system therapy for childhood leukemia. , 1989, The American journal of pediatric hematology/oncology.

[68]  D. Cox.  Regression Models and Life-Tables , 1972 .